-
Mashup Score: 0Allogeneic CT0596 Shows Early Activity, Safety in R/R Myeloma - 3 hour(s) ago
CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 1
Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
Ribociclib plus endocrine therapy produced similar pCR rates to standard chemotherapy in HR-positive, HER2-negative breast cancer. Read more below. #BCsm #breastcancer #oncology #nurse https://t.co/Tz2UGFzbaJ
-
-
Mashup Score: 0
Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
Disitamab vedotin plus toripalimab increased PFS and OS in the first line of therapy for patients with HER2-positive metastatic urothelial cancer. Read more below. #bladdercancer #urothelialcancer #oncology #nurse https://t.co/6oaVrJZN5Q
-
-
Mashup Score: 0
The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
A nurse practitioner at @UCSFHospitals explained some of the factors that should be considered when selecting a frontline CDK4/6 inhibitor for HR+ breast cancer. Read more below. #BCsm #oncology #nursing https://t.co/guH4EYtwx4
-
-
Mashup Score: 0Ibrutinib/Nivolumab Yields Activity in Relapsed CNS Lymphoma - 4 day(s) ago
Three of 18 patients had remissions lasting over 2 years in a study of ibrutinib plus nivolumab for relapsed/refractory CNS lymphoma.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
The combination of ibrutinib and nivolumab showed efficacy and tolerability in patients with relapsed/refractory CNS lymphoma. Read more below. #oncology #lymphoma #nurse #nursing https://t.co/TzP1QaAP0V
-
-
Mashup Score: 0Retifanlimab Receives FDA Approval for Advanced Anal Cancer - 5 day(s) ago
Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
🚨 BREAKING: The FDA has approved retifanlimab both as a monotherapy and in combination with chemotherapy for use in advanced squamous cell carcinoma of the anal canal. Read more below. #analcancer #cancernews #oncology #nurse #FDA #nursing https://t.co/Dv4TzE4EOJ
-
-
Mashup Score: 0Injection Time Can Encourage Bonding During Myeloma Care - 5 day(s) ago
The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
Heather Wenberg, BSN, RN, OCN, recommends using the injection time for subcutaneous daratumumab to get to know patients better. 🎥 Watch the full video: https://t.co/35ChLh4JwR https://t.co/wDHckOWWtQ #MMsm #myeloma #oncology #nursing #bestpractice #cancercare #nurse https://t.co/LQnLOIvQ5g
-
-
Mashup Score: 1
The addition of bevacizumab to capecitabine produced favorable efficacy and safety data for older patients with metastatic colorectal cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
The combination of bevacizumab and capecitabine yielded promising safety and efficacy data in older patients with mCRC. Read more below. #mCRC #CRCsm #oncology #nurse #nursing https://t.co/d7c95yuhRS
-
-
Mashup Score: 0
Telisotuzumab vedotin-tllv has earned accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
🚨BREAKING: Telisotuzumab vedotin-tllv has received accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression. Read more below. #lungcancer #oncology #FDAnews #nurse #nursing https://t.co/C1eQWMsfNN
-
-
Mashup Score: 0
Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet-
🚨BREAKING: The FDA has approved belzutifan for use in adult and pediatric patients 12 or older with pheochromocytoma or paraganglioma. Read more below. #HNCsm #oncology #nurse #nursing https://t.co/EoMKf9zuW1
-
CAR T-cell therapy CT0596 showed early efficacy and safety signs in patients with relapsed/refractory multiple myeloma. Read more below. #MMsm #myeloma #hematology #oncology #nurse https://t.co/m9XQvM3l2N